Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
ETRM's Cash-to-Debt is ranked higher than
91% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. ETRM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ETRM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.8  Med: 4.44 Max: No Debt
Current: No Debt
Equity-to-Asset 0.83
ETRM's Equity-to-Asset is ranked lower than
77% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ETRM: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
ETRM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.24  Med: 0.37 Max: 0.83
Current: 0.83
-0.24
0.83
Piotroski F-Score: 5
Altman Z-Score: -16.96
Beneish M-Score: -3.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -2953.25
ETRM's Operating Margin % is ranked lower than
97% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. ETRM: -2953.25 )
Ranked among companies with meaningful Operating Margin % only.
ETRM' s Operating Margin % Range Over the Past 10 Years
Min: -9543.49  Med: -7250.48 Max: -2896.57
Current: -2953.25
-9543.49
-2896.57
Net Margin % -3088.48
ETRM's Net Margin % is ranked lower than
97% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. ETRM: -3088.48 )
Ranked among companies with meaningful Net Margin % only.
ETRM' s Net Margin % Range Over the Past 10 Years
Min: -8732.53  Med: -7543.41 Max: -2968.36
Current: -3088.48
-8732.53
-2968.36
ROE % -678.99
ETRM's ROE % is ranked lower than
99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ETRM: -678.99 )
Ranked among companies with meaningful ROE % only.
ETRM' s ROE % Range Over the Past 10 Years
Min: -706.62  Med: -170.6 Max: -77.38
Current: -678.99
-706.62
-77.38
ROA % -168.56
ETRM's ROA % is ranked lower than
95% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. ETRM: -168.56 )
Ranked among companies with meaningful ROA % only.
ETRM' s ROA % Range Over the Past 10 Years
Min: -250.82  Med: -92.49 Max: -60.09
Current: -168.56
-250.82
-60.09
ROC (Joel Greenblatt) % -8792.75
ETRM's ROC (Joel Greenblatt) % is ranked lower than
95% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. ETRM: -8792.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ETRM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8792.75  Med: -3135.24 Max: -575.02
Current: -8792.75
-8792.75
-575.02
3-Year EBITDA Growth Rate -59.80
ETRM's 3-Year EBITDA Growth Rate is ranked lower than
97% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. ETRM: -59.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ETRM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -54.3 Max: -21.3
Current: -59.8
3-Year EPS without NRI Growth Rate -57.60
ETRM's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ETRM: -57.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ETRM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -56.25 Max: -21.6
Current: -57.6
GuruFocus has detected 3 Warning Signs with EnteroMedics Inc $ETRM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ETRM's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ETRM Guru Trades in Q2 2016

Jim Simons 250,538 sh (New)
» More
Q3 2016

ETRM Guru Trades in Q3 2016

Jim Simons 3,931,399 sh (+1469.18%)
» More
Q4 2016

ETRM Guru Trades in Q4 2016

Jim Simons 162,765 sh (+189.80%)
» More
Q1 2017

ETRM Guru Trades in Q1 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ETRM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:OTCPK:LCTC, OTCPK:DIZTF, OTCPK:FGCN, OTCPK:GIDYL, NAS:KOOL, OTCPK:VICA, OTCPK:QTVLF, AMEX:ELMD, NAS:MGCD, OTCPK:BSGM, OTCPK:ZMSPF, NAS:MDVX, OTCPK:RMSL, OTCPK:MRIC, OTCPK:TLTFF, NAS:LLIT, NAS:RWLK, NAS:TNDM, OTCPK:AVMXF, OTCPK:BLOZF » details
Traded in other countries:BY8E.Germany,
Headquarter Location:USA
EnteroMedics Inc is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders.

EnteroMedics is a development-stage medical device firm focused on the emerging area of neuromodulation. Its lead implantable device is aimed at the obesity market and suffered from unfavorable data from an earlier pivotal trial. Results of the most recent pivotal trial should be released over the next couple of quarters. Aside from the Maestro system, the firm does not have any other candidates in the pipeline, but it plans to apply the same technology to Type 2 diabetes and hypertension.

Ratios

vs
industry
vs
history
PB Ratio 1.94
ETRM's PB Ratio is ranked lower than
68% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. ETRM: 1.94 )
Ranked among companies with meaningful PB Ratio only.
ETRM' s PB Ratio Range Over the Past 10 Years
Min: 1.61  Med: 4.1 Max: 60.56
Current: 1.94
1.61
60.56
PS Ratio 2.03
ETRM's PS Ratio is ranked higher than
66% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ETRM: 2.03 )
Ranked among companies with meaningful PS Ratio only.
ETRM' s PS Ratio Range Over the Past 10 Years
Min: 0.64  Med: 237.64 Max: 1113.18
Current: 2.03
0.64
1113.18
EV-to-EBIT -0.78
ETRM's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. ETRM: -0.78 )
Ranked among companies with meaningful EV-to-EBIT only.
ETRM' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.1  Med: -1.5 Max: -0.1
Current: -0.78
-6.1
-0.1
EV-to-EBITDA -0.78
ETRM's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. ETRM: -0.78 )
Ranked among companies with meaningful EV-to-EBITDA only.
ETRM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2  Med: -1.5 Max: -0.1
Current: -0.78
-6.2
-0.1
Current Ratio 5.61
ETRM's Current Ratio is ranked lower than
80% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. ETRM: 5.61 )
Ranked among companies with meaningful Current Ratio only.
ETRM' s Current Ratio Range Over the Past 10 Years
Min: 1.01  Med: 3.24 Max: 9.46
Current: 5.61
1.01
9.46
Quick Ratio 5.15
ETRM's Quick Ratio is ranked lower than
80% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. ETRM: 5.15 )
Ranked among companies with meaningful Quick Ratio only.
ETRM' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.07 Max: 9.46
Current: 5.15
0.81
9.46
Days Inventory 1.00
ETRM's Days Inventory is ranked higher than
99% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. ETRM: 1.00 )
Ranked among companies with meaningful Days Inventory only.
ETRM' s Days Inventory Range Over the Past 10 Years
Min: 1  Med: 1840.73 Max: 3893.82
Current: 1
1
3893.82
Days Sales Outstanding 32.87
ETRM's Days Sales Outstanding is ranked higher than
54% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. ETRM: 32.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
ETRM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.87  Med: 66.79 Max: 72.5
Current: 32.87
32.87
72.5
Days Payable 462.97
ETRM's Days Payable is ranked lower than
98% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ETRM: 462.97 )
Ranked among companies with meaningful Days Payable only.
ETRM' s Days Payable Range Over the Past 10 Years
Min: 462.97  Med: 536.49 Max: 1111.09
Current: 462.97
462.97
1111.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -241.50
ETRM's 3-Year Average Share Buyback Ratio is ranked lower than
98% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ETRM: -241.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ETRM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -241.5  Med: -30.85 Max: 0
Current: -241.5
-241.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.34
ETRM's Price-to-Net-Cash is ranked lower than
99.99% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. ETRM: 2.34 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ETRM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.02  Med: 7.5 Max: 1050.77
Current: 2.34
2.02
1050.77
Price-to-Net-Current-Asset-Value 2.04
ETRM's Price-to-Net-Current-Asset-Value is ranked lower than
58% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. ETRM: 2.04 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ETRM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.78  Med: 6.3 Max: 561.19
Current: 2.04
1.78
561.19
Price-to-Tangible-Book 1.94
ETRM's Price-to-Tangible-Book is ranked lower than
56% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. ETRM: 1.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ETRM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.63  Med: 5.25 Max: 89.97
Current: 1.94
1.63
89.97
Price-to-Median-PS-Value 0.01
ETRM's Price-to-Median-PS-Value is ranked lower than
99.99% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ETRM: 0.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ETRM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.87 Max: 2.84
Current: 0.01
0.01
2.84
Earnings Yield (Greenblatt) % -125.65
ETRM's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ETRM: -125.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ETRM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -196.08  Med: 2974 Max: 44250.5
Current: -125.65
-196.08
44250.5

More Statistics

Revenue (TTM) (Mil) $0.76
EPS (TTM) $ -15.70
Beta2.64
Short Percentage of Float13.17%
52-Week Range $1.75 - 53.18
Shares Outstanding (Mil)6.91

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -262.49 -126.00
EPS without NRI ($) -262.49 -126.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ETRM

Headlines

Articles On GuruFocus.com
EnteroMedics Announces the Acquisition of the Gastric Vest System May 23 2017 
EnteroMedics Announces First Quarter 2017 Financial Results and Conference Call May 16 2017 
EnteroMedics to Host First Quarter 2017 Conference Call May 11 2017 
EnteroMedics' vBloc® Neurometabolic Therapy Recognized at 2017 Edison Awards Apr 24 2017 
Kevin Douglas Bets on EnteroMedics; Popeyes and AMERCO Top Estimates May 28 2015 
Canaccord Genuity Remains Bullish on EnteroMedics Following Q4 Earnings Feb 19 2015 
Analysts Are Bullish On EnteroMedics Following FDA Approval Of Obesity Treatment Jan 16 2015 
EnteroMedics Inc. Reports Operating Results (10-K) Mar 07 2011 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 08 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 06 2010 

More From Other Websites
EnteroMedics snaps up maker of obesity 'vest' May 24 2017
EnteroMedics Announces the Acquisition of the Gastric Vest System May 23 2017
Edited Transcript of ETRM earnings conference call or presentation 16-May-17 12:30pm GMT May 21 2017
EnteroMedics Announces First vBloc® Neurometabolic Therapy Implant at McGuire Veterans Affairs... May 18 2017
EnteroMedics reports 1Q loss May 16 2017
EnteroMedics Announces First Quarter 2017 Financial Results and Conference Call May 16 2017
EnteroMedics to Host First Quarter 2017 Conference Call May 11 2017
EnteroMedics' vBloc® Neurometabolic Therapy Recognized at 2017 Edison Awards Apr 24 2017
EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Mar 16 2017
Here's Why EnteroMedics (ETRM) Stock Soared Today Mar 14 2017
EnteroMedics' vBloc® Neurometabolic Therapy Featured on "The Doctors" TV Show Mar 13 2017
EnteroMedics Reports Fourth Quarter 2016 Financial Results Mar 07 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating EnteroMedics Inc. for Potential... Feb 21 2017
EnteroMedics Regains Compliance With Nasdaq Listing Requirement Feb 21 2017
EnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal... Feb 09 2017
EnteroMedics Announces Closing of $19.0 Million Underwritten Public Offering and Full Exercise of... Jan 23 2017
Biotech Movers: Illumina, Inc. (ILMN) And EnteroMedics Inc (ETRM) Jan 12 2017
Stock Market Roundup, Jan. 10: NVDA Self-Driving Cars, ETRM Soars Jan 10 2017
Still Struggling to Put Money to Work Jan 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}